公开(公告)号：US20250051345A1

公开(公告)日：2025-02-13

申请号：US18718953

申请日：2022-12-12

Applicant: Novartis AG

Inventor： Simon Krautwald ,  Jianliang Lu ,  James Anthony Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  A61K31/444

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.